Q-omics provides the consensus-scored SNORA11F profile across patient tissues and cancer cell-line models. SNORA11F expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNORA11F is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNORA11F RNA expression shows 18,943 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where SNORA11F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA11F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA11F survival associations across molecular data types. SNORA11F RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA11F RNA expression–survival associations across cancer types. High SNORA11F expression shows unfavorable associations in UVM, KIRC, ACC, UCEC and MESO, but favorable associations in READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNORA11F RNA expression.
This table summarizes SNORA11F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA11F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA11F shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LUAD, UCEC and BLCA. The COAD box plot shows higher SNORA11F RNA expression in tumor versus normal tissue (log2 FC = +0.869, t-test p < 0.001).
This table shows molecular features associated with SNORA11F in patient tissues and cancer cell lines. In patient samples, SNORA11F shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
